Clinical trials: Trop2
Solid Tumor Cancer, Locally Advanced
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a…
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Urothelial Cancer
- Trial name
- NCT07193511
- Testing
- AVZO-103, Combination Agent
- Where
- 15 sites in United States
- Volunteers
- 355 people
- Sponsor
- Avenzo Therapeutics, Inc.
Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
This is a multicenter, open-label, multi-cohort Phase II exploratory study designed to evaluate the efficacy and safety of sacituzumab tirumotecan with or without tislelizumab in patients with unresectable, locally advanced, or…
- Conditions
- Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma
- Trial name
- NCT07068542
- Testing
- Sacituzumab Tirumotecan (SKB264) plus Tislelizumab, Sacituzumab Tirumotecan (SKB264)
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Zhejiang Provincial People's Hospital
Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and Tagitanlimab (KL-A167) in the treatment…
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation
- Trial name
- NCT07179783
- Testing
- Sacituzumab Tirumotecan, Tagitanlimab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Second Hospital
Advanced Biliary Tract Cancer(BTC)
Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer
This is a single-arm, Phase II, multicenter clinical trial evaluating sacituzumab tirumotecan in patients with TROP2-positive advanced biliary tract cancer who have experienced disease progression after, or intolerance to, at…
- Trial name
- NCT07701122
- Testing
- Sacituzumab Tirumotecan (SKB264)
- Volunteers
- 33 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This is an single-arm, multicenter phase II study to evaluate the safety and efficacy of Sacituzumab Tirumotecan (sac-TMT) plus anlotinib in previously treated extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- STAR-01 (NCT07501169)
- Testing
- Sacituzumab Tirumotecan and Anlotinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sichuan University
Oral Squamous Cell Carcinoma (OSCC)
A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma
This study is a multicenter, prospective, single-arm Phase II clinical trial evaluating the efficacy and safety of neoadjuvant therapy with TROP-2 ADC in combination with toripalimab for resectable locally advanced oral squamous…
- Trial name
- NCT07778368
- Testing
- Sacituzumab Govitecan OR Sacituzumab Tirumotecan in Combination with Toripalimab, Radical Surgery for OSCC, Radiation Therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai East Hospital
Squamous Cell Carcinoma
Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions
This is a phase 1, single-arm, open-label, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of TGFBR2 TROP2 CAR/IL15 NK cells in patients with…
- Trial name
- NCT07631013
- Testing
- TROP2 CAR/IL-15 TGFBR2 KO NK cells
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer ( HER2 Negative)
Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
This study aims to evaluate whether ^68Ga-TROP2 PET/CT, combined with ^18F-FDG PET/CT, can predict the efficacy of anti-TROP2 antibody-drug conjugates in patients with advanced HER2-negative breast cancer.
- Trial name
- NCT07471776
- Testing
- Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan, 68Ga-TROP2 PET/CT Imaging, 18F-FDG PET Imaging
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- Fudan University
TNBC - Triple-Negative Breast Cancer
Trop-2 Targeted PET Probes in Advanced TNBC
According to inclusion and exclusion criteria, 20 eligible subjects with triple-negative breast cancer (TNBC) scheduled to receive sacituzumab govitecan were screened.
- Trial name
- NCT07046455
- Testing
- Sacituzumab Govitecan (SG)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Squamous Cell Carcinoma
Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to investigate the efficacy and safety of sacituzumab govitecan in patients with advanced esophageal squamous cell carcinoma.
- Trial name
- SG-ESCC (NCT06329869)
- Testing
- Sacituzumab govitecan
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- National Taiwan University Hospital
TNBC, Brain Metastasis
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
This is a single-arm, multi-center phase II study to evaluate the safety and efficacy Sacituzumab Tirumotecan (Sac-TMT) plus bevacizumab in triple-negative breast cancer patients with brain metastases.
- Trial name
- NCT07623577
- Testing
- Sacituzumab Tirumotecan (Sac-TMT), bevacizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Fudan University
Metastatic Solid Tumors
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).
- Trial name
- NCT04319198
- Testing
- Sacituzumab Govitecan-hiy
- Where
- 21 sites in United States, Belgium and 1 more
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences
Craniopharyngioma
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients
This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.
- Trial name
- NCT07177482
- Testing
- 68Ga-MY6349 PET/CT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Deling Li
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
Advanced Biliary Tract Cancers
A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
This is a prospective, single-arm, Phase II study evaluating sacituzumab tirumotecan combined with envafolimab in patients with TROP2-positive advanced biliary tract cancers who have progressed on first-line immunochemotherapy.
- Trial name
- NCT07729033
- Testing
- Sacituzumab tirumotecan combined with envafolimab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine…
- Trial name
- NCT05104866
- Testing
- Dato-DXd, Capecitabine, Gemcitabine
- Where
- 167 sites in United States, Argentina and 18 more
- Volunteers
- 732 people
- Sponsor
- AstraZeneca
Tumor, Solid Tumor
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors
The objective of the study is to construct a noninvasive approach 68Ga-MY6349 PET/CT to detect the Trop-2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from Trop-2 targeting…
- Conditions
- Tumor, Solid Tumor, Positron-Emission Tomography
- Trial name
- NCT06188468
- Testing
- standard-of-care imaging (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE PET/CT), 68Ga-MY6349 PET/CT
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
Participants With Advanced Solid Tumor Malignancies
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
This study is a multicenter, open-label, multi-dose, first-in-human (FIH) Phase I/IIa study to determine the safety and tolerability of VBC103, as well as the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D)…
- Trial name
- NCT07299747
- Testing
- VBC103
- Where
- China
- Volunteers
- 255 people
- Sponsor
- VelaVigo Bio Inc
Breast Cancer, Trop2
PET/CT for Trop2 ADC Response Evaluation Cancers
To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.
- Conditions
- Breast Cancer, Trop2, PET/CT
- Trial name
- NCT07046689
- Testing
- 68Ga-MY6349 PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
Sacituzumab govitEcan in THYroid Cancers
SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated…
- Trial name
- SETHY (NCT06235216)
- Testing
- Sacituzumab govitecan
- Where
- 11 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos